|
|
|
|
Cubist Pharma submits 2 INDs with US FDA
Cubist Pharmaceuticals, Inc submitted two Investigational New Drug Applications (INDs) with the US Food and Drug Administration (FDA) on December 23rd.The INDs signify the company's intentions to begin clinical investigation (human trials...
|
|
|
Occurrence and Characteristics of Class 1 and 2 Integrons in Pseudomonas aeruginosa Isolates from Patients in
Xu Z et al.- Class 1 and 2 integrons were detected in 45.8% (54/118) and 19.5% (23/118) of the tested Pseudomonas aeruginosa isolates, respectively. Three strains were positive for both the integrons. This is the first report of...
|
|
|
Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections
Cubist Pharmaceuticals, Inc.(NASDAQ: CBST) today announced that the company submitted two Investigational New Drug Applications (INDs) with the U.S. Food and Drug Administration (FDA) on December 23rd. The INDs signify the companys...
|
|
|
Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc.(NASDAQ: CBST - News) today announced that the company submitted two Investigational New Drug Applications (INDs) with the U.S. Food and Drug Administration (FDA) on...
|
|
|
Cubist Pharmaceuticals, the Developer of Cubicin, Announces Submission of 2 INDs Targeting Serious Infections
Cubist President and CEO Mike Bonney said, These INDs demonstrate our continued commitment to building a significant product pipeline in the acute care setting.I am particularly proud that both of these antibiotic candidates are based on...
|
|
|
Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections
Cubist President and CEO Mike Bonney said, These INDs demonstrate our continued commitment to building a significant product pipeline in the acute care setting.I am particularly proud that both of these antibiotic candidates are based on...
|
|
|
The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofi
Jang CH et al.- The piperacillin-tazobactam coated tympanostomy tube showed resistance to CRPA biofilm formation. The piperacillin-tazobactam coating may be useful to reduce CRPA biofilm formation. The use of piperacillin-tazobactam...
|
|
|
Intercell initiates Phase II Pseudomonas aeruginosa vaccine trial
In the Phase II clinical trial, mechanically ventilated intensive care patients, who are at particular high risk of acquiring severe and often life-threatening forms of Pseudomonas aeruginosa infections, such as ventilator-associated...
|
|
|
Product Development Update: Intercell Starts Phase II Clinical Trial for Pseudomonas Aeruginosa Vaccine and FD
Initiation of a Phase II clinical trial in mechanically ventilated intensive care patients Study aims to investigate immunogenicity and safety in intensive care patients and to assess Pseudomonas aeruginosa infection rates Initial...
|
|
|
Intercell initiates Phase II Pseudomonas aeruginosa vaccine trial
Austria-based biotechnology company Intercell has initiated a Phase II clinical trial with its vaccine candidate to prevent infections with the bacterium Pseudomonas aeruginosa.Intercell's vaccine is a recombinant subunit vaccine...
|
|
|
Intercell begins phase II trial for Pseudomonas aeruginosa vaccine
Intercell AG announced that the phase-II clinical trial with the company's vaccine candidate to prevent infections with the bacterium Pseudomonas aeruginosa is starting.Intercell's vaccine (IC43) is a recombinant subunit vaccine...
|
|
|
New findings from Creighton University describe advances in Pseudomonas aeruginosa
- (NewsRx.com) -- According to recent research from the United States, 'AmpD indirectly regulates the production of AmpC beta-lactamase via the cell wall recycling pathway (see also Pseudomonas aeruginosa).Recent publications have...
|
|
|
The Electricidal Effect: Reduction of Staphylococcus and Pseudomonas Biofilms by Prolonged Exposure to Low-Int
The Electricidal Effect: Reduction of Staphylococcus and Pseudomonas Biofilms by The Electricidal Effect: Reduction of Staphylococcus and Pseudomonas Biofilms by Prolonged Exposure to Low-Int.
|
|
|
Polysorbate 80 Inhibition of Pseudomonas aeruginosa Biofilm Formation and Its Cleavage by the Secreted Lipase
Surface-associated bacterial communities known as biofilms are an important source of nosocomial infections.Microorganisms such as Pseudomonas aeruginosa can colonize the abiotic surfaces of medical implants, leading to chronic...
|
|
|
KPC-2-Producing Enterobacter cloacae and Pseudomonas putida Coinfection in a Liver Transplant Recipient
KPC-2-Producing Enterobacter cloacae and Pseudomonas putida Coinfection in a Liv KPC-2-Producing Enterobacter cloacae and Pseudomonas putida Coinfection in a Liver Transplant Recipient.
|
|
|
Vital hospital therapy pool still closed after six-month problem
A HOSPITAL'S hydrotherapy pool vital to help relieve pain in arthritis sufferers and physiotherapy patients has been closed for nearly seven months because of contamination.The facility at St Albans City Hospital is used for post...
|
|
|
Effect of Electrical Current on the Activities of Antimicrobial Agents against Pseudomonas aeruginosa, Staphyl
Effect of Electrical Current on the Activities of Antimicrobial Agents against P Effect of Electrical Current on the Activities of Antimicrobial Agents against Pseudomonas aeruginosa, Staphyl.
|
|
|
Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime aga
Evidence is mounting in support of the inoculum effect (i.e., slow killing at large initial inocula [CFUo]) for numerous antimicrobials against a variety of pathogens.Our objectives were to (i) determine the impact of the CFUo of ...
|
|
|
In Vitro Activities of a Novel Nanoemulsion against Burkholderia and Other Multidrug-Resistant Cystic Fibrosis
Respiratory tract infection, most often involving opportunistic bacterial species with broad-spectrum antibiotic resistance, is the primary cause of death in persons with cystic fibrosis (CF).Species within the Burkholderia cepacia...
|
|
|
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
-KaloBios Pharmaceuticals, Inc.today announced that the company has raised an additional $12 million in the second closing of its Series D venture financing, which along with the $20 million it raised in September brings the round to $32...
|
|
|
KaloBios Raises $12 Million Series D
5AM VenturesAlloy Ventures Baxter International Inc GBS Ventures Mitsubishi UFJ Capital MPM Capital nzyme Ventures Singapore Bio-Innovations Sofinnova Ventures KaloBios Pharmaceuticals, Inc.raised $12 million for its second closing on a...
|
|
|
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
- KaloBios Pharmaceuticals, Inc.today announced that the company has raised an additional $12 million in the second closing of its Series D venture financing, which along with the $20 million it raised in September brings the round to $32...
|
|
|
KaloBios Pharmaceuticals, Inc. Raises Additional $12 Million in Series D Venture Financing for a New Total of
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- today announced that the company has raised an additional $12 million in the second closing of its Series D venture financing, which along with the $20 million it raised in September brings the...
|
|
|
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
We are very pleased to add significantly to this financing round in a very challenging environment, said David Pritchard, KaloBios' President and Chief Executive Officer.This achievement reflects our investors' appreciation of the value...
|
|
|
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million
KaloBios Pharmaceuticals, Inc.today announced that the company has raised an additional $12 million in the second closing of its Series D venture financing, which along with the $20 million it raised in September brings the round to $32...
|
